$1.66
-0.24 (-12.63%)
Open$1.93
Previous Close$1.90
Day High$1.95
Day Low$1.65
52W High$11.88
52W Low$1.78
Volume—
Avg Volume52.7K
Market Cap54.14M
P/E Ratio—
EPS$-2.09
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+1,278.9% upside
Current
$1.66
$1.66
Target
$22.89
$22.89
$19.41
$22.89 avg
$38.59
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 21.76M | 20.47M | 20.59M |
| Net Income | 3.46M | 2.44M | 2.89M |
| Profit Margin | 15.9% | 11.9% | 14.1% |
| EBITDA | 6.13M | 5.18M | 5.24M |
| Free Cash Flow | 2.45M | 2.75M | 2.72M |
| Rev Growth | +16.8% | +12.7% | +4.6% |
| Debt/Equity | 0.77 | 0.70 | 0.64 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |